InSite Vision starts late-stage trial of cataract surgery drug

InSite Vision Inc. has started enrolling patients in a Phase III trial of a drug to reduce pain and inflammation after cataract surgery. The Alameda company (OTC BB: INSV) will enroll about 240 patients in the two-arm trial of ISV-303, or BromSite, the company said Tuesday. Results from this first of two late-stage BromSite trials are expected in late 2012 or early 2013.

See the San Francisco Business Times data base of clinical trials by Bay Area drug-development companies.